The UK's National Screening Committee (NSC) has narrowed its prostate cancer screening recommendations, advising that only a few thousand British men with a specific genetic mutation should undergo testing. This decision marks a significant shift from broader screening practices and is based on an extensive analysis of the risks and benefits. Prostate cancer remains the most common cancer among men in the United Kingdom, causing approximately 12,000 deaths annually.

However, the committee, chaired by Professor Sir Mike Richards, concluded that the harms of over-diagnosis and unnecessary treatment for most men outweigh the potential benefits of widespread screening. The NSC's analysis indicates that testing asymptomatic men can indeed save lives, but it also leads to unnecessary treatments. These treatments often result in adverse effects such as urinary incontinence, erectile dysfunction, and reliance on absorbent products.

For every 1,000 men screened around the age of 50, the committee found that while two lives might be saved over the next 15 years, about 20 men would be diagnosed with cancers that would never have threatened their lives. Sir Mike Richards, who has personal experience with prostate cancer, emphasized the challenge in determining which tumors require treatment. "Once prostate cancer is discovered, it is not yet possible to say with sufficient precision which tumors require treatment and which do not," he stated.

This uncertainty contributes to the decision to limit screening to a specific group. The new recommendations specifically target men with a BRCA2 gene mutation combined with a family history of breast, ovarian, pancreatic, or prostate cancer. The BRCA2 gene is known for its role in DNA repair, and mutations in this gene are linked to more aggressive forms of cancer.

The committee suggests these men undergo a PSA test every two years between the ages of 45 and 61. This targeted approach affects only a few thousand men annually, some of whom are already monitored in genetic clinics. The committee's decision reflects a more restrictive stance compared to previous guidelines, which included men with BRCA1 mutations as well.

Romania's medical crisis: A call for systemic reform

Private health providers demand withdrawal of CNAS capacity algorithm

Despite the targeted nature of these recommendations, the subject of prostate cancer screening continues to be a contentious issue in the UK. Public figures such as former prime ministers, Olympic athletes, and actors have weighed in on the debate, advocating for broader awareness and action. Notably, Sir Chris Hoy has been diagnosed with terminal prostate cancer, and public calls for increased attention come from figures like David Cameron, Rishi Sunak, Stephen Fry, and Les Ferdinand.

Charitable organizations have also maintained pressure on the government to expand screening. Chiara De Biase from Prostate Cancer UK argues that a broader program could save thousands of lives, though she acknowledges that current evidence does not yet support a favorable benefit-risk ratio for the general population. The committee has reiterated that screening is not recommended for all men, including Black men, who are at double the risk of developing the disease, as well as those with a general family history of cancer.

This exclusion is due to the lack of precise criteria to effectively identify those at risk without leading to over-diagnosis. Research continues to evolve, with new prostate cancer tests and artificial intelligence-based tools under consideration. The Transform study, which investigates risk specifically in Black men, is also being closely monitored.

However, researchers have yet to determine if the forms of cancer affecting this group are inherently more aggressive. Sir Mike Richards expressed hope that as more evidence emerges, better tests and a deeper understanding of the disease might allow for an expanded screening program in the future. Until such evidence is available, the committee's recommendations will remain focused on the small group of men with BRCA2 mutations.

As research progresses, the key question remains: when will we have the evidence needed to expand screening safely and effectively?